Thu, Dec 18, 2014, 1:43 PM EST - U.S. Markets close in 2 hrs 17 mins


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • redhot47fla redhot47fla Nov 7, 2013 9:19 AM Flag

    ASH Abstract - Adcetris in frontline multi-agent non-Hodgkins - "substantial anti-tumor activity"

    Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas:

    All 26 pts were assessed for a clinical response at the end of treatment with A+CHP. The ORR was 100%, with a CR rate of 88%. All 7 non-ALCL pts achieved a CR. After a median observation time of 16 months, the 1-year PFS rate was 71% (95% CI 49, 85).


    At a dose of 1.8 mg/kg, brentuximab vedotin, administered sequentially with CHOP or in combination with CHP, exhibited manageable toxicity in the treatment of newly-diagnosed CD30+ mature T/NK-cell lymphomas. A+CHP exhibited substantial antitumor activity, with an ORR of 100% (CR rate 88%) and a 1-year PFS rate of 71%. A phase 3 study comparing A+CHP to CHOP in the frontline treatment of mature T-cell lymphomas is underway ( NCT01777152).

33.515+1.375(+4.28%)1:43 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.